[{"orgOrder":0,"company":"DreamTec Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Undisclosed"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"National Children's Hospital, Vietnam","sponsor":"Anabio R&D","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Children's Hospital, Vietnam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Children's Hospital, Vietnam \/ Anabio R&D","highestDevelopmentStatusID":"1","companyTruncated":"National Children's Hospital, Vietnam \/ Anabio R&D"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"VIETNAM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Helse Stavanger | ADM Protexin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Edinburgh \/ Helse Stavanger | ADM Protexin","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ Helse Stavanger | ADM Protexin"}]

Find Clinical Drug Pipeline Developments & Deals for Bacillus Subtilis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Anabio R&D

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Anabio R&D

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Bacillus Subtilis

                          Therapeutic Area : Gastroenterology

                          Study Phase : Undisclosed

                          Sponsor : Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Inflammatory Bowel Diseases.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Bacillus Subtilis

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Edinburgh

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          University of Edinburgh

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Parkinson Disease.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          July 05, 2024

                          Lead Product(s) : Bacillus Subtilis

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Helse Stavanger | ADM Protexin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          National Children's Hospital, Vietnam

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          National Children's Hospital, Vietnam

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Respiratory Tract Infections.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : Bacillus Subtilis

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Anabio R&D

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Anabio R&D

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Anabio R&D

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Respiratory Tract Infections.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          April 07, 2023

                          Lead Product(s) : Bacillus Subtilis

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Thai Binh University of Medicine and Pharmacy

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Bacillus Subtilis

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Undisclosed

                          Sponsor : Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          February 15, 2022

                          Lead Product(s) : Bacillus Subtilis

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          September 27, 2021

                          Lead Product(s) : Bacillus Subtilis

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank